mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

The mammalian target of rapamycin (mTOR) is dysregulated in diverse cancers and contributes to tumor progression and drug resistance. The first generation of mTOR inhibitors have failed to show clinical efficiency in treating pancreatic cancers due in part to the feedback relief of the insulin-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Feng, Zhang, Yandong, Geng, Li, Zhang, Ping, Wang, Guangyi, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346894/
https://www.ncbi.nlm.nih.gov/pubmed/25654224
http://dx.doi.org/10.3390/ijms16023267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346894/
https://www.ncbi.nlm.nih.gov/pubmed/25654224
http://dx.doi.org/10.3390/ijms16023267

Ejemplares similares